Possibly, the restoration of DN memory B cells to normal circulating levels in RA patients after treatment with either TNF-inhibitors or tocilizumab reflects a state of chronic B cell hyperactivity dependent on TNF and IL-6 [10, 11], which is inhibited by treatment. Here, IL6 is linked to rheumatoid arthritis.